Hepatitis B And The Prevention Of Primary Cancer Of The Liver

This important book comprises a narrative account of research on the hepatitis B virus (and related subjects) and selected reprints from the laboratory of Nobel laureate Baruch S Blumberg and his colleagues. The hepatitis B virus (HBV) is one of the ten most common deadly infectious diseases and is responsible for 1.1 million deaths a year worldwide. Research in his laboratory resulted in the discovery of HBV and the invention of the vaccine which protects one against it. The research began as an apparently esoteric study of human biochemical and immunologic variation. This required field-work in Africa, the Arctic, the Pacific, the Americas, and in many other locations and populations. The overall goal was to identify inherited biological differences which were related to differing responses to disease-causing agents. The virus was discovered using the blood of an infected person who had developed the antibody, to detect the virus present in another infected person who had become a carrier of the virus. Screening of blood donors led to the near-elimination of post-transfusion hepatitis B. There are now national HBV vaccination programs in more than 70 countries. During the past decade these programs have strikingly reduced the prevalence of HBV in many countries and there has been a significant drop in the incidence of cancer of the liver in the vaccinated cohorts. The HBV vaccination program is now, after smoking cessation, the most widely used cancer prevention program in the world. Contents:Early Training and ResearchGenetic PolymorphismThe Study of Transfused Patients, 1960The Institute for Cancer Research, Fox Chase Cancer Center, 1964–1997Australia Antigen and the Hepatitis B Virus, 1964Control of Post-Transfusion Hepatitis B, 1969Invention of Hepatitis B Vaccine, 1969HBV and Primary Cancer of the Liver, 1969Iron and Iron-Binding Proteins, 1974HBV, Genetics, and Related Topics, 1967Methods of Transmission, 1967Anti-ViralsMiscellaneous, Ephemeral, and Unpublished ArticlesHepatitis B Virus. A Subjective View Readership: Students in human biology and researchers in virology, vaccinology, genetics, anthropology, history & sociology of science, public health and the scientific method. keywords:Hepatitis B Virus;Vaccine for HBV;Primary Cancer of the Liver;Cancer Vaccine;Prevention;Basic Research;Genetics of Susceptibility;Fox Chase Cancer Center;Suriname;Genetic Polymorphisms

The global epidemic of hepatitis B and C is a serious public health problem. Hepatitis B and C are the major causes of chronic liver disease and liver cancer in the world. In the next 10 years, 150,000 people in the United States will die from liver disease or liver cancer associated with chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infections. Today, between 800,000 and 1.4 million people in the United States have chronic hepatitis B and between 2.7 and 3.9 million have chronic hepatitis C. People most at risk for hepatitis B and C often are the least likely to have access to medical services. Reducing the rates of illness and death associated with these diseases will require greater awareness and knowledge among health care workers, improved identification of at-risk people, and improved access to medical care. Hepatitis B is a vaccine-preventable disease. Although federal public health officials recommend that all newborns, children, and at-risk adults receive the vaccine, about 46,000 new acute cases of the HBV infection emerge each year, including 1,000 in infants who acquire the infection during birth from their HBV-positive mothers. Unfortunately, there is no vaccine for hepatitis C, which is transmitted by direct exposure to infectious blood. Hepatitis and Liver Cancer identifies missed opportunities related to the prevention and control of HBV and HCV infections. The book presents ways to reduce the numbers of new HBV and HCV infections and the morbidity and mortality related to chronic viral hepatitis. It identifies priorities for research, policy, and action geared toward federal, state, and local public health officials, stakeholder, and advocacy groups and professional organizations.

This book provides a comprehensive overview of the current limitations and unmet needs in Hepatocellular Carcinoma (HCC) diagnosis, treatment, and prevention. It also provides newly emerging concepts, approaches, and technologies to address challenges. Topics covered include changing landscape of HCC etiologies in association with health disparities, framework of clinical management algorithm, new and experimental modalities of HCC diagnosis and prognostication, multidisciplinary treatment options including rapidly evolving molecular targeted therapies and immune therapies, multi-omics molecular characterization, and clinically relevant experimental models. The book is intended to assist collaboration between the diverse disciplines and facilitate forward and reverse translation between basic and clinical research by providing a comprehensive overview of relevant areas, covering epidemiological trend and population-level patient management strategies, new diagnostic and prognostic tools, recent advances in the standard care and novel therapeutic approaches, and new concepts in pathogenesis and experimental approaches and tools, by experts and opinion leaders in their respective fields. By thoroughly and concisely covering whole aspects of HCC care, Hepatocellular Carcinoma serves as a valuable reference for multidisciplinary readers, and promotes the development of personalized precision care strategies that lead to substantial improvement of disease burden and patient prognosis in HCC.

Testing and diagnosis of hepatitis B (HBV) and C (HCV) infection is the gateway for access to both prevention and treatment services, and is a crucial component of an effective response to the hepatitis epidemic. Early identification of persons with chronic HBV or HCV infection enables them to receive the necessary care and treatment to prevent or delay progression of liver disease. Testing also provides an opportunity to link people to interventions to reduce transmission, through counselling on risk behaviors and provision of prevention commodities (such as sterile needles and syringes) and hepatitis B vaccination. These are the first WHO guidelines on testing for chronic HBV and HCV infection and complement published guidance by WHO on the prevention, care and treatment of chronic hepatitis C and hepatitis B infection. These guidelines outline the public health approach to strengthening and expanding current testing practices for HBV and HCV, and are intended for use across age groups and populations.

More than 180 participants and experts from 31 countries met for the fifth time in 10 years in St. Gallen, Switzerland for a 3-day conference to discuss important current issues of clinical cancer prevention. The meeting was again organized and co-sponsored by St. Gallen Oncology Conferences (SONK). While SONK has been extremely successful in organizing large international c- gresses on “Primary Therapy of Early Breast Cancer” as well as “Supportive Care in Cancer” for more than 20 years, the idea of promoting interdisciplinary, clinically oriented meetings on cancer prevention is a more recent and not yet generally accepted and w- comed concept in modern oncology. Since today’s medical expenses are soaring and me- cal research budgets are stagnating or even being cut, neither politicians nor industry is willing to risk an additional unpredictable channel of expenses, such as that demanded by clinical cancer prevention efforts! In Switzerland—and we fear in many other parts of the globe—some 97%–98% or even a greater percentage of health budgets is spent for curative and palliative/rehabilitative m- icine. Since a meager 2%–3% of national health budgets is for preventive medicine, even less than that proportion is specifically allocated for cancer prevention. When the money for “curing and caring” for the diseased populace runs short, there is likely not much left for partly controversial disease prevention in the (still) healthy part of the population.

About 375 million people are infected with the hepatitis B virus. It has killed more people than AIDS and also causes millions of cases of liver cancer. The discovery of this deadly virus and the vaccine against it--a vaccine that is sharply decreasing the infection rate worldwide and is probably the first effective cancer vaccine--was one of the great triumphs of twentieth-century medicine. And it almost didn't happen. With wit and insight, this scientific memoir and story of discovery describes how Baruch Blumberg and a team of researchers found a virus they were not looking for and created a vaccine for a disease they previously knew little about--work that took the author around the world and won him the Nobel Prize. Blumberg and his collaborators were investigating relationships between gene distribution and disease susceptibility, research that was yielding interesting data but no real breakthroughs. Many viewed their work as more field trip than science. But, through decades of hard work and investigative twists and turns, their pursuit led to the hepatitis B antigen, the elusive virus itself, and, ultimately, the vaccine. As he takes the reader through the detective work that culminated in his incredible discovery, the author recounts with immediacy exciting moments in the lab and in the field--from a hair-raising flight to Africa to an unpleasant encounter with Alaskan sled dogs. The hepatitis B story is more than a fascinating chronicle of a major discovery. What Blumberg followed to the virus was a trail of remarkable "accidents" that happen when scientists seek answers to interesting questions. Those events, combined with the investigator's determined persistence, resulted in studies that generated a pharmaceutical industry, have far-flung public-health applications, and saved millions of lives.

This important book comprises a narrative account of research on the hepatitis B virus (and related subjects) and selected reprints from the laboratory of Nobel laureate Baruch S Blumberg and his colleagues. The hepatitis B virus (HBV) is one of the ten most common deadly infectious diseases and is responsible for 1.1 million deaths a year worldwide.Research in his laboratory resulted in the discovery of HBV and the invention of the vaccine which protects one against it. The research began as an apparently esoteric study of human biochemical and immunologic variation. This required field-work in Africa, the Arctic, the Pacific, the Americas, and in many other locations and populations. The overall goal was to identify inherited biological differences which were related to differing responses to disease-causing agents. The virus was discovered using the blood of an infected person who had developed the antibody, to detect the virus present in another infected person who had become a carrier of the virus. Screening of blood donors led to the near-elimination of post-transfusion hepatitis B.There are now national HBV vaccination programs in more than 70 countries. During the past decade these programs have strikingly reduced the prevalence of HBV in many countries and there has been a significant drop in the incidence of cancer of the liver in the vaccinated cohorts. The HBV vaccination program is now, after smoking cessation, the most widely used cancer prevention program in the world.

These are the first World Health Organization (WHO) guidelines for theprevention care and treatment of persons living with CHB infection andcomplement similar recent published guidance by WHO on the prevention care and treatment of infection due to the hepatitis C virus (HCV). In contrastto several recent international guidelines on the management of CHB infectionfrom the United States Europe Asia-Pacific and the United Kingdom (UK) theprimary audience for these WHO guidelines is country programme managers inall settings but particularly in LMICs to help plan the development and scale up.